Verrica Pharmaceuticals Inc. PE Ratio
The price-to-earnings (P/E) ratio tells you how many dollars investors pay for each dollar of a company's annual profit. It is market capitalization divided by net income over the trailing four quarters, meaning the four most recent filed quarters added together, and the table shows both amounts. A higher P/E means investors are paying more for each dollar of current earnings, often because they expect profits to grow; a negative P/E means the company lost money over those four quarters. Each point uses the filed share count and the last closing price on or before that quarter-end date, never today's price.
- Verrica Pharmaceuticals Inc. pe ratio for the quarter ending 2026-06-30 was -3.39, a change of -3.28 year-over-year.
- Verrica Pharmaceuticals Inc. pe ratio for the quarter ending 2026-03-31 was -5.05, a change of 1.1 year-over-year.
- Verrica Pharmaceuticals Inc. pe ratio for the quarter ending 2025-12-31 was -8.03, a change of -7.19 year-over-year.
- Verrica Pharmaceuticals Inc. pe ratio for the quarter ending 2025-09-30 was -1.58, a change of 6.2 year-over-year.
- Verrica Pharmaceuticals Inc. pe ratio for fiscal 2026 was -3.39.
- Verrica Pharmaceuticals Inc. pe ratio for fiscal 2025 was -8.03, a change of -7.19 from fiscal 2024.
- Verrica Pharmaceuticals Inc. pe ratio for fiscal 2024 was -0.84, a change of 45.5 from fiscal 2023.
- Verrica Pharmaceuticals Inc. pe ratio for fiscal 2023 was -46.34, a change of -0.19 from fiscal 2022.
- Available history
- 2018-06-30 to 2026-06-30
- Data captured
Historical PE Ratio
Annual PE Ratio
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |